Hikma Pharmaceuticals logo

HIK - Hikma Pharmaceuticals Share Price

1965.5p 29.0  1.5%

Last Trade - 24/01/20

Large Cap
Market Cap £4.76bn
Enterprise Value £5.04bn
Revenue £1.63bn
Position in Universe 180th / 1830
Unlock HIK Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


HIK Revenue Unlock HIK Revenue

Net Income

HIK Net Income Unlock HIK Revenue

Normalised EPS

HIK Normalised EPS Unlock HIK Revenue

PE Ratio Range

HIK PE Ratio Range Unlock HIK Revenue

Dividend Yield Range

HIK Dividend Yield Range Unlock HIK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HIK EPS Forecasts Unlock HIK Revenue
Profile Summary

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated September 8, 2005
Public Since November 1, 2005
No. of Shareholders: n/a
No. of Employees: 8,413
Sector Healthcare
Industry Pharmaceuticals
Index FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSE Euromid , FTSE 350 , FTSE 350 Lower Yield , FTSE 350 Pharmaceuticals & Biotechnology , FTSE 100 , ,
Exchange London Stock Exchange (Full)
Shares in Issue 242,319,174
Free Float (0.0%)
Eligible for
HIK Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for HIK
Upcoming Events for HIK
Thursday 27th February, 2020
Full Year 2019 Hikma Pharmaceuticals PLC Earnings Release
Friday 15th May, 2020 Estimate
Hikma Pharmaceuticals PLC Annual Shareholders Meeting
Similar to HIK
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.